Approximately 20–30% of patients with NSCLC are present with brainmetastases. The standard management for brainmetastases is radiotherapy. Despite the administration of radiation therapy for brainmetastases, the prognosis is still poor. The poor prognosis is related to the progression of extracranial lesions. Therefore, systemic therapy is important to improve survival of patients with brainmetastases. EGF receptor-tyrosine kinase inhibitor (EGFR–TKI) is a standard treatment for advanced NSCLC patients with sensitive EGFRmutations and is also effective in controlling brainmetastasis in such patients. Upfront EGFR–TKI therapy might be one of the treatment choices for EGFR–mutant NSCLC patients with asymptomatic brainmetastases. However, it is unclear whether upfront EGFR–TKI or radiation therapy is more preferable. New EGFR–TKIs and combination with existing EGFR–TKIs and other drugs are being investigated for treatment options. Further investigations are required to determine the future direction for management of EGFR–mutant NSCLC patients with brainmetastasis.